| dc.contributor.author | Kennedy, Cormac | |
| dc.contributor.author | Hennessy, Martina | |
| dc.date.accessioned | 2024-02-06T12:55:39Z | |
| dc.date.available | 2024-02-06T12:55:39Z | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2021 | en |
| dc.identifier.citation | Kennedy C., Ali O., Farnan R., Hall M., Stinson J., O'Connor P., Hennessy M., Barry M., Is it time to reconsider the treatment paradigm for obese patients with hypertension?, Journal of Human Hypertension, 2022 May;36(5):482-484 | en |
| dc.identifier.issn | 14765527 09509240 | |
| dc.identifier.other | Y | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | The recent STEP trials reported blood pressure reductions for obese patients treated with semaglutide. We analyzed a cohort of
patients attending our hypertension clinic and found that 26% were severely or morbidly obese and morbidly obese patients
frequently had resistant hypertension (41%). We suggest semaglutide may be an effective anti-hypertensive agent for obese
patients with resistant hypertension and this hypothesis should be assessed in randomized clinical trials. | en |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | Journal of Human Hypertension; | |
| dc.rights | Y | en |
| dc.title | Is it time to reconsider the treatment paradigm for obese patients with hypertension? | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/mhenness | |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/kennec30 | |
| dc.identifier.rssinternalid | 236036 | |
| dc.identifier.doi | http://dx.doi.org/10.1038/s41371-021-00630-4 | |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.orcid_id | 0000-0002-2153-5288 | |
| dc.identifier.uri | http://hdl.handle.net/2262/104857 | |
